Opus Genetics, Inc. (IRD)

NCM – Real Time Price. Currency in USD

3.94

+0.06 (1.55%)

Market open: Aug 12, 2026, 11:08 AM EDT

3.88

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.12 per share a year ago.

06.08.2026

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

03.08.2026

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Topline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) program Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the last patient has been enrolled in its registrational Phase 3 clinical trial evaluating OPGx-LCA5, the Company's investigational gene therapy for LCA5-associated inherited retinal disease.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
IRD	TD Cowen	Buy	undefined >> undefined	July 29th 2026

Press releases

06.08.2026

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

03.08.2026

Opus Genetics, Inc. (IRD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Opus Genetics, Inc. (IRD)

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Videos

No Data

Upgrades / Downgrades

Press releases

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Videos

No Data

Upgrades / Downgrades

Press releases

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Search stocks

Opus Genetics, Inc. (IRD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Opus Genetics, Inc. (IRD)

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Videos

No Data

Upgrades / Downgrades

Press releases

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Videos

No Data

Upgrades / Downgrades

Press releases

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease